Corvus Pharmaceuticals (CRVS) Corporate presentation summary

Strategic positioning and pipeline

• Focus on first-in-class oral immune modulators targeting ITK, with broad potential across immune diseases including dermatology, pulmonology, gastroenterology, and rheumatology.

• Strong intellectual property protection through 2042 and a leadership team with experience in developing major immunology drugs.

• Ongoing and planned clinical trials in atopic dermatitis (AD), PTCL, hidradenitis suppurativa, and asthma.

Mechanism of action and scientific rationale

• Soquelitinib is a highly selective ITK inhibitor, blocking Th2 and Th17 pathways, rebalancing immune responses, and increasing regulatory T cells (Tregs).

• Demonstrates specificity over other kinases and modulates multiple inflammatory cytokines, restoring immune balance.

• Biomarker data confirm reduction in Th2/Th17 cells and cytokines, supporting the novel mechanism.

Clinical efficacy and safety in atopic dermatitis

• Phase 1 placebo-controlled trial showed 75% of patients achieved EASI 75 and 33% achieved IGA 0/1 after 8 weeks of soquelitinib.

• Durable remission observed post-treatment, with efficacy in patients previously treated with systemic therapies, including those resistant to other treatments.

• Safety profile consistent across cohorts, with no severe or serious adverse events and no discontinuations due to adverse events.